ADA Scientific Sessions 2025 Abstract

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 Tablet, an Oral Dual GLP-1/GIP Receptor Agonist, in Healthy Participants—A Phase 1 Study

By Wei Hu, Yijun Du, Qian Zhang, Lu Li

Trial in peopleInterventions

The paper

Wei Hu, Yijun Du, Qian Zhang, Lu Li

Hefei

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, poster 797-P

doi.org/10.2337/db25-797-p

Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity